Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics total assets
Total assets on the balance sheet at the end of each period.
Opus Genetics's total assets was $95.30M at Sep 30, 2026. For fiscal 2025 it was $50.24M, up 36.3% from the year before. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $53.95M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.24M | +36.3% |
| FY2024 | Dec 31, 2024 | $36.86M | -31.7% |
| FY2023 | Dec 31, 2023 | $53.95M | +10.1% |
| FY2022 | Dec 31, 2022 | $48.99M | +87.9% |
| FY2021 | Dec 31, 2021 | $26.08M | +47.5% |
| FY2020 | Dec 31, 2020 | $17.68M | +891.1% |
| FY2019 | Dec 31, 2019 | $1.78M | -88.9% |
| FY2018 | Dec 31, 2018 | $16.04M | -43.3% |
| FY2017 | Dec 31, 2017 | $28.29M | +34.4% |
| FY2016 | Dec 31, 2016 | $21.04M | -15.2% |
| FY2015 | Dec 31, 2015 | $24.81M | -26.0% |
| FY2014 | Dec 31, 2014 | $33.53M | +71.5% |
| FY2013 | Dec 31, 2013 | $19.56M | +31.1% |
| FY2012 | Dec 31, 2012 | $14.92M | +9.0% |
| FY2011 | Dec 31, 2011 | $13.69M | -15.6% |
| FY2010 | Dec 31, 2010 | $16.22M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $95.30M | +163.8% |
| Q2 FY2026 | Jun 30, 2026 | $92.97M | +140.4% |
| Q1 FY2026 | Mar 31, 2026 | $66.79M | +38.7% |
| Q4 FY2025 | Dec 31, 2025 | $50.24M | +36.3% |
| Q3 FY2025 | Sep 30, 2025 | $36.12M | -10.6% |
| Q2 FY2025 | Jun 30, 2025 | $38.67M | -13.8% |
| Q1 FY2025 | Mar 31, 2025 | $48.17M | -7.1% |
| Q4 FY2024 | Dec 31, 2024 | $36.86M | -31.7% |
| Q3 FY2024 | Sep 30, 2024 | $40.39M | -25.5% |
| Q2 FY2024 | Jun 30, 2024 | $44.83M | +3.1% |
| Q1 FY2024 | Mar 31, 2024 | $51.84M | +14.2% |
| Q4 FY2023 | Dec 31, 2023 | $53.95M | +10.1% |
| Q3 FY2023 | Sep 30, 2023 | $54.19M | +272.0% |
| Q2 FY2023 | Jun 30, 2023 | $43.47M | +142.8% |
| Q1 FY2023 | Mar 31, 2023 | $45.40M | +121.6% |
| Q4 FY2022 | Dec 31, 2022 | $48.99M | +87.9% |
| Q3 FY2022 | Sep 30, 2022 | $14.57M | -37.2% |
| Q2 FY2022 | Jun 30, 2022 | $17.90M | -29.1% |
| Q1 FY2022 | Mar 31, 2022 | $20.49M | +68.9% |
| Q4 FY2021 | Dec 31, 2021 | $26.08M | +47.5% |
| Q3 FY2021 | Sep 30, 2021 | $23.20M | +162.7% |
| Q2 FY2021 | Jun 30, 2021 | $25.25M | +146.4% |
| Q1 FY2021 | Mar 31, 2021 | $12.13M | +5.0% |
| Q4 FY2020 | Dec 31, 2020 | $17.68M | +891.1% |
| Q3 FY2020 | Sep 30, 2020 | $8.83M | -41.0% |
| Q2 FY2020 | Jun 30, 2020 | $10.25M | -42.0% |
| Q1 FY2020 | Mar 31, 2020 | $11.55M | -40.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.78M | -88.9% |
| Q3 FY2019 | Sep 30, 2019 | $14.98M | +8.0% |
| Q2 FY2019 | Jun 30, 2019 | $17.68M | -3.1% |
| Q1 FY2019 | Mar 31, 2019 | $19.43M | -13.9% |
| Q4 FY2018 | Dec 31, 2018 | $16.04M | -43.3% |
| Q3 FY2018 | Sep 30, 2018 | $13.87M | -43.6% |
| Q2 FY2018 | Jun 30, 2018 | $18.24M | -35.1% |
| Q1 FY2018 | Mar 31, 2018 | $22.55M | +15.2% |
| Q4 FY2017 | Dec 31, 2017 | $28.29M | +34.4% |
| Q3 FY2017 | Sep 30, 2017 | $24.59M | – |
| Q2 FY2017 | Jun 30, 2017 | $28.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.58M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.04M | – |
See a number that looks wrong?